This is a open-label, 3+3 design, dose escalation and expansion, phase I study, to evaluate
the safety and tolerability, and to determine the RP2D of TR128 when administered qd in
patients with advanced solid tumors. Up to 5 cohorts of 3-6 patients each will be treated in
dose escalation phase of the study. One cycle is 28 days. Dose expansion phase to further
evaluate the safety, tolerability and preliminary anti-tumor activity of TR128 at the RP2D.